Skip to main content

Three deaths reported due to contaminated Penicillin injection



The Ghana FDA department dispatched a Pharmacovigilance team to investigate the death of 3 patients caused due to contaminated Benzathine Penicillin injection. The preliminary investigations revealed that due to contaminated 0.9 normal saline solution which was used in reconstituting Penicillin powder for injection had led to fatality of the patients.

The primary cause of death was determined to be injection site abscess, other serious adverse drug reaction included were skin necrosis and ulcers. The reason for contamination was stated as the re use of normal saline solution for several days at the Health Centre in the Asuogyaman District. In the statement regarding Benzathine Penicillin, it has been clearly indicated that sterile water should be used for reconstitution.

The healthcare professionals have been asked to be more vigilant and report any untoward medical occurrence through submitting adverse event forms to the FDA or even by direct contact through the available hotline numbers.

Reference:


Brought to you by: 
Think-i (www.thinki.in)  , Quality driven Solution providers in Clinical research and Pharmacovigilance

We at Think I are committed to provide cost effective & robust pharmacovigilance solutions.
Think I partners with AB Cube, France to provide SafetyEasy PV™ pharmacovigilance database which is fully evolutive and pre-validated, hosted through cloud based technology and delivered through software as a solution (SaaS) in a web based access.

Comments

Popular posts from this blog

Pharmacovigilance system- Industry perspective, Market size and Operations

Monitoring adverse drug reaction is an essential component in patient safety. In the last decade we have seen how technology has influenced the entire healthcare system, leading to patient awareness, thus making the pharmaceutical companies and regulatory authorities to invest more time and resource in monitoring adverse events.
Pharmacovigilance as per WHO is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem Pharmacovigilance is the study of adverse events taking into account all the plausible relationship or untoward medical occurrence which the patent experienced after taking the drug and then using standard set of coordinated activities which involves first collecting adverse event reports either via telephone, email, social network, lay press , media. After adverse event reports are filed we then process and assess these reports in database to determine if indeed these adv…

The ‘new’ EUDRAVIGILANCE

European Medical Agency would be releasing a new version of EudraVigilance system, which is expected to go live in November 2017, EMA in their report mentioned that they would be publishing a checklist of readiness for all the stakeholders to prepare them for the changes which will come along with the launch of the revised version of EudraVigilance, for which EMA also intends to provide eLearning modules, support webinars and face to face training.
The prototype of EudraVigilance test environment or XCOMP is already scheduled to be released June 2017 which will let all the National competent authorities to test Individual case safety reports in E2B R3 versions.
We at Think I are also driven to produce Pharmacovigilancesafety  database solutions using cloud based technology which are not only cost effective and user friendly but also fully validated for quick, easy import, entry and electronic submissions of adverse event. 
For more details, contact us at +91 9560102587, +91 9810068241 or…

Drug Safety and Br-exit

There have been talks about what would happen once UK leaves EU which has put lot of QPPV (Qualified Persons Responsible for Pharmacovigilance) in UK in dilemma as the regulations say that the QPPV should be a part of the EU, with the impact Brexit it will hit the pharmacovigilance system in UK as EU would not be obliged to carry out Post marketing surveillance in UK.

Currently June Raine who is chairing the Pharmacovigilance Risk Assessment Committee ( part of the European Medical Agency, in which there are two members from each member state) is from the Medicines and healthcare products regulatory agency (MHRA) of the UK.
There have been discussions about QPPV who still want to be a part of EU which might eventually lead to a negotiation between EMA and UK to collaborate pharmacovigilance activities together, as pharmacovigilance is above politics.
By Joseph Mathew Sr. Manager- Think i

About us: We are an organization providing technological solutions and result oriented quality service…